This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
Nature medicine, 30(7), 2037-2048
Citation
Sanyal, Arun J; Kaplan, Lee M; Frias, Juan P; Brouwers, Bram; Wu, Qiwei; Thomas, Melissa K; Harris, Charles; Schloot, Nanette C; Du, Yu; Mather, Kieren J; Haupt, Axel; Hartman, Mark L. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.. Nature medicine, 30(7), 2037-2048. https://doi.org/10.1038/s41591-024-03018-2